This year’s Japan Annual Meeting offers interactive and exciting sessions and networking opportunities for professions involved in the discovery, development and lifecycle management of pharmaceuticals, biotechnology and related health care products..
Tokyo, Japan (PRWEB) October 05, 2012
DIA, the premier organization dedicated to knowledge exchange that fosters innovation to raise the level of health and well-being worldwide will host the 9th DIA Japan Annual Meeting at the Toshi Center Hotel, Tokyo, Japan on November 19-21.
The meeting offers three times more sessions than last year, under the theme of Importance of Development Strategies for Life Cycle Management of Safe and Effective Medical Products: “What can we do from the start of development to benefit patients?”
It is three days of interacting with biopharmaceutical industry, contract service organizations, regulatory agencies, health ministries, patient organizations, universities and students from throughout Japan and worldwide. This year’s program is comprised of 6 tracks related to various interest areas such as Clinical Operations, Regulatory Affairs, Clinical Statistics, Clinical Safety and Pharmacovigilance, Project Management, Data Management, Chemistry, Manufacturing and Controls (CMC), Medical Writing, SixSigma, Health Technology Assessment (HTA), Patients Advocacy. Informative tutorials, outstanding speakers, excellent presenters, interactive sessions and exciting network opportunities await all attendees. This meeting also included the DIA Awards Presentation, with presenter and DIA Board President Ling Su, PhD.
The 9th Annual Meeting also includes two keynote speakers, Peter Bachmann, DrSc, European and International Affairs Member of the CMDh (Co-ordination Group for Mutual Recognition Decentralised Procedures - Human) on the Latest Regulatory Environment in EU - from Development to Post-Marketing; and Takao Yamori, PhD, Director of Center for Product Evaluation, Pharmaceuticals and Medical Devices Agency (PMDA) to discuss the New Drug Development of Japan Origin through Industry-Academia Collaboration.
In the afternoon of Day 3, there are two special sessions of roundtable discussion: the first session is focus on Benefit-risk Evaluations by FDA, EMA and PMDA, inviting Dr. Peter Bachmann, Dr. Gerald Dal Pan, Director of Office of Surveillance and Epidemiology, CDER, FDA and Mr. Kazuhiko Mori, Chief Safety Officer of Pharmaceuticals and Medical Devices Agency (PMDA). The last session of the meeting is the PMDA Town Hall with a theme of “Future of Pharmacovigellance and Regulatory.”
This year’s Japan Annual Meeting offers interactive, informative and exciting sessions and networking opportunities for professions involved in the discovery, development and lifecycle management of pharmaceuticals, biotechnology and related health care products.
Register for 9th DIA Japan Annual Meeting here.
DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices and related medical products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well being worldwide. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland; Tokyo, Japan; Mumbai, India; and Beijing, China. http://www.diahome.org. Follow DIA on Facebook, Twitter, LinkedIn, and YouTube.